glp-1 shortages As Drug Shortage Ends, Why Will Patients Pay More? The GLP-1 drug shortage is

In a trial in people with metabolic syndrome, pasteurized Akkermansia increased GLP-1 ( Suenaert et al., 2026 (Human trial)

Participants were excluded if they had a self-reported diagnosis of psychiatric disorders not subject of NESDA (e.g

Supporting energy levels is often the first noticeable benefit as liver function improves

neither holds a Marketing Authorisation in the UK or EU

Novo Nordisk's CagriSema, targeting over 20% weight loss, and Eli Lilly's retatrutide, showing a 24% weight reduction in early trials, are notable candidates

It has likewise been shown to be a critical component in the reduction, softening, and re-elasticizing of keloid scars inside and out